Inclusion Criteria

          1. ≥18 years of age at the time of study enrollment

          2. Biopsy-confirmed primary or metastatic carcinoma with involvement of the lung, liver,
             adrenal gland, pancreas, kidney, and/or abdominal/pelvic lymph node that would receive
             SABR

          3. Any lesion that would receive SABR is no larger than 5 cm in greatest dimension

          4. 1-10 total lesions that would receive SABR

          5. If multiple lesions are treated, they must be at least 3 cm apart

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          7. Life expectancy at least 6 months

          8. Women of childbearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control, abstinence) prior to study entry and for
             the duration of study participation. Should a woman become pregnant or suspect she is
             pregnant while participating in this study, she must inform her treating physician
             immediately.

        Exclusion criteria

          1. Contraindication to having an MRI scan

          2. Central or ultracentral lung tumor defined as a lesion located within 2cm of the
             trachea and proximal bronchial tree for which patient is receiving SABR to a separate
             site that would receive SABR on this study.

          3. Cytotoxic chemotherapy or investigational agent within 2 weeks of stereotactic body
             radiation therapy (SBRT)

          4. Presence of uncontrolled brain metastases, spinal cord compression, or leptomeningeal
             carcinomatosis

          5. Any unresolved toxicity (Common Terminology Criteria for Adverse Events version 5.0 >
             grade 2) from previous anti-cancer therapy

          6. Any condition in the opinion of the investigator that would interfere with evaluation
             of study treatment or interpretation of patient safety or study results

          7. Prior radiation therapy that directly overlaps any radiation therapy given in this
             study

          8. Prior radiation therapy that could lead to an unacceptably high risk of clinically
             significant normal tissue injury due to high cumulative normal tissue dose as
             determined by the investigator

          9. Female patients who are pregnant or breastfeeding